-
Mashup Score: 20
BACKGROUND: Resistant hypertension is characterized by elevated blood pressure (BP) despite using 3 antihypertensive agents. Ambulatory BP monitoring (ABPM) detects the presence of white-coat resistant hypertension (24-hour BP <130/80 mm Hg). The aim of the study was to evaluate risks of death in resistant hypertension compared with controlled hypertension, as well as in ABPM-confirmed (24-hour BP ≥130 or 80 mm Hg), versus white-coat resistant hypertension. METHODS: We selected 8146 patients with controlled hypertension (office BP <140/90 mm Hg while being treated with ≤3 antihypertensive drugs) and 8577 with resistant hypertension (BP ≥140 or ≥90 mm Hg while being treated with ≥3 drugs). All-cause and cardiovascular mortalities (median follow-up, 9.7 years) were compared between groups, as well as between patients with white-coat (3289) and ABPM-confirmed (5288) resistant hypertension. Hazard ratios (HRs) from Cox models after adjustment for clinical confounders were used for comparis
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 3Hypertension Call for Submissions - 1 day(s) ago
May is Preeclampsia Awareness Month. To raise awareness of this life-threatening hypertensive disorder of pregnancy, Hypertension will publish a special issue focusing on pregnancy related hypertension. Hypertension invites submissions representing the best of pregnancy related hypertension science which will be published in May of 2025. Manuscript types to be included will be original research articles, research letters and reviews. This themed issue will be led by Ananth Karumanchi MD. Deadline for
Source: www.ahajournals.orgCategories: General Medicine News, Cardiology News and JournTweet-
Call for Manuscripts Here, Get your Call for Manuscript Here! May is Preeclampsia Awareness Month. To raise awareness, Hypertension will publish a special issue focusing on pregnancy related hypertension. For more information, please see: https://t.co/NjiWTVqUsm
-
-
Mashup Score: 77Blood Pressure–Lowering Medications, Sodium Reduction, and Blood Pressure | Hypertension - 2 day(s) ago
BACKGROUND: Both blood pressure–lowering medication and sodium reduction are effective in hypertension control, but whether the effect of sodium reduction differ across blood pressure–lowering medications is unclear. This study aims to evaluate the dose-response effect of sodium intake reduction on blood pressure in treated hypertensive individuals and the impact of different classes of blood pressure–lowering drugs. METHODS: We searched multiple databases and reference lists up to July 9, 2024. Randomized controlled trials with a duration of ≥2 weeks comparing the effect of different levels of sodium intake (measured by 24-hour urinary sodium excretion) on blood pressure in hypertensive individuals treated with constant blood pressure–lowering medications were included. Instrumental variable meta-analyses based on random-effects models were conducted to evaluate the dose effect of sodium reduction on blood pressure. Subgroup analyses were performed based on the class of blood pressure
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet-
Reducing sodium intake lowers blood pressure in treated hypertensives as effectively as in untreated ones, but not all BP-lowering medications respond to sodium reduction in the same way @JingSongEpi @SPombo86 @actiononsalt @CphpQmul @QMUL_WIPH @QMUL@Fe... https://t.co/797d3MS6EG https://t.co/jz8pnbT06R
-
-
Mashup Score: 17
The Hypertension Education Editors, in conjunction with the AHA Council on Hypertension SCILL committee, present a webinar in the journal’s #HypEdSeries: AHA Centennial Webinar – Hypertension Treatment Trials: Past, Present and Future Registration Link: https://heart.zoom.us/webinar/register/WN_v69lKgwXSEu1GZ-k23nZIQ Webinar Passcode: 715926 Tuesday, December 10, 2024 2:00 pm – 3:00 pm CDT Presented by: Raymond Townsend MD, Ernesto Schiffrin, MD, PhD, and Naomi Fisher, MD Webinar Moderator: Stella Daskalopoulou, MD, MSc, PhD, DIC Chat Moderator: J. Mathew Luther, MD, MSCI Tentative Format (total time = 60 minutes): -15-20 minutes PAST: Raymond Townsend – Landmark trials -10-15 minutes PRESENT: Ernesto Schiffrin – SPRINT through current FDA-approved drugs -10-15 minutes FUTURE: Naomi Fisher – Devices and current phase 2 or 3 trials with promise -10 minutes Q&A (Moderators, Speaker, Panelists and Audience)
Source: heart.zoom.usCategories: General Medicine News, CardiologistsTweet-
!Register today!: https://t.co/jmqsqX43ei to join mods Stella Daskalopoulou and Matt Luther for a @HyperAHA #HypEdSeries Webinar presented by @ESchiffrin @LDI_ILD @McGill_DOM Dec 10, 2024 2pm – 3pm CT AHA Centennial Webinar - HTN Treatment Trials: Past, Present and Future https://t.co/R3E66PNGZF
-
-
Mashup Score: 24GPER Stimulation Attenuates Cardiac Dysfunction in a Rat Model of Preeclampsia | Hypertension - 3 day(s) ago
BACKGROUND: Preeclampsia poses a substantial clinical challenge, characterized by maternal hypertension, cardiac dysfunction, and persistent cardiovascular risks for both the mother and offspring. Despite the known roles of the estrogen receptor (GPER [G protein-coupled estrogen receptor]) in placental development, its impact on cardiovascular aspects within a preeclampsia animal model remains unexplored. We propose that G-1, a GPER agonist, could have the potential to regulate not only hypertension but also cardiac dysfunction in rats with preeclampsia. METHODS: To explore the influence of G-1 on preeclampsia, we used the reduced uterine perfusion pressure (RUPP) model. RUPP rats were administered either G-1 (100 µg/kg per day) or hydralazine (25 mg/kg per day). We conducted echocardiography to probe the intricate cardiac effects of G-1. RESULTS: The RUPP rat model revealed signs of hypertension and cardiac dysfunction and alterations in gene and protein expression within placental an
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet-
GPER Stimulation Attenuates Cardiac Dysfunction in a Rat Model of Preeclampsia @allankdc @lab_lindsey https://t.co/G9ESNJtRk9 https://t.co/nOEEi9KkIe
-
-
Mashup Score: 69Prevalence and Risk Factors for Secondary Hypertension in Young Adults | Hypertension - 3 day(s) ago
BACKGROUND: The prevalence of secondary causes of hypertension in young adults is unknown, and therefore, there is no consensus about the indication of screening of secondary hypertension (2HTN) in this population. The objective was to report the prevalence and the causes of 2HTN in young subjects. METHODS: In this cross-sectional study, 2090 patients with confirmed hypertension aged 18 to 40 years with full workup for 2HTN screening were included. We assessed the prevalence of 2HTN and analyzed the factors associated. RESULTS: Among 2090 patients, 619 (29.6%) had a 2HTN. The most frequent diagnoses of 2HTN in descending order were primary aldosteronism (n=339; 54.8%), renovascular hypertension (n=114; 18.4%), primary kidney disease (n=80; 12.9%), pheochromocytoma/functional paraganglioma (n=37; 5.9%), hypertension caused by drugs or substances (n=32; 6.0%), and other diagnoses (n=17; 2.7%). Patients with blood pressure <160/100 mm Hg did not have a lower prevalence of 2HTN regardless
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet-
Prevalence and risk factors for secondary Hypertension in young adults @AmarLaurence @frauti @jbdefrem https://t.co/7H9SyfaGYI https://t.co/NF9eBdnvCr
-
-
Mashup Score: 24GPER Stimulation Attenuates Cardiac Dysfunction in a Rat Model of Preeclampsia | Hypertension - 3 day(s) ago
BACKGROUND: Preeclampsia poses a substantial clinical challenge, characterized by maternal hypertension, cardiac dysfunction, and persistent cardiovascular risks for both the mother and offspring. Despite the known roles of the estrogen receptor (GPER [G protein-coupled estrogen receptor]) in placental development, its impact on cardiovascular aspects within a preeclampsia animal model remains unexplored. We propose that G-1, a GPER agonist, could have the potential to regulate not only hypertension but also cardiac dysfunction in rats with preeclampsia. METHODS: To explore the influence of G-1 on preeclampsia, we used the reduced uterine perfusion pressure (RUPP) model. RUPP rats were administered either G-1 (100 µg/kg per day) or hydralazine (25 mg/kg per day). We conducted echocardiography to probe the intricate cardiac effects of G-1. RESULTS: The RUPP rat model revealed signs of hypertension and cardiac dysfunction and alterations in gene and protein expression within placental an
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet-
GPER Stimulation Attenuates Cardiac Dysfunction in a Rat Model of Preeclampsia @allankdc @lab_lindsey https://t.co/G9ESNJtRk9 https://t.co/nOEEi9KkIe
-
-
Mashup Score: 24GPER Stimulation Attenuates Cardiac Dysfunction in a Rat Model of Preeclampsia | Hypertension - 4 day(s) ago
BACKGROUND: Preeclampsia poses a substantial clinical challenge, characterized by maternal hypertension, cardiac dysfunction, and persistent cardiovascular risks for both the mother and offspring. Despite the known roles of the estrogen receptor (GPER [G protein-coupled estrogen receptor]) in placental development, its impact on cardiovascular aspects within a preeclampsia animal model remains unexplored. We propose that G-1, a GPER agonist, could have the potential to regulate not only hypertension but also cardiac dysfunction in rats with preeclampsia. METHODS: To explore the influence of G-1 on preeclampsia, we used the reduced uterine perfusion pressure (RUPP) model. RUPP rats were administered either G-1 (100 µg/kg per day) or hydralazine (25 mg/kg per day). We conducted echocardiography to probe the intricate cardiac effects of G-1. RESULTS: The RUPP rat model revealed signs of hypertension and cardiac dysfunction and alterations in gene and protein expression within placental an
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet-
GPER Stimulation Attenuates Cardiac Dysfunction in a Rat Model of Preeclampsia @allankdc @lab_lindsey https://t.co/G9ESNJtRk9 https://t.co/nOEEi9KkIe
-
-
Mashup Score: 37Optimal Antihypertensive Systolic Blood Pressure: A Systematic Review and Meta-Analysis | Hypertension - 4 day(s) ago
BACKGROUND: Systolic blood pressure (SBP) lowering reduces major cardiovascular disease (CVD) and all-cause mortality. However, the optimal target for SBP lowering remains controversial. METHODS: We included trials with random allocation to an SBP <130 mm Hg treatment target and CVD as the primary outcome. Data were extracted from each study independently and in duplicate using a standardized protocol. Random-effects meta-analysis was used to obtain pooled hazard ratios (HRs) and 95% CIs for CVD and all-cause mortality comparing SBP <130 and ≥130 mm Hg treatment targets. A secondary analysis compared the same outcomes for randomization to an SBP target of <120 or <140 mm Hg. RESULTS: Seven trials, including 72 138 participants, met the eligibility criteria. Compared with an SBP target of ≥130 mm Hg, an SBP target of <130 mm Hg significantly reduced major CVD (HR, 0.78 [95% CI, 0.70–0.87]) and all-cause mortality (HR, 0.89 [95% CI, 0.79–0.99]). Compared with an SBP target of <140 mm Hg,
Source: www.ahajournals.orgCategories: General Medicine News, Cardiology News and JournTweet-
What are optimal antihypertensive BP treatment targets? This study validates an SBP target <130 mm Hg to prevent cardiovascular disease and mortality and supports an SBP target of <120 mm Hg. https://t.co/sj9Gk9rUOw https://t.co/HZxIN03RDh
-
-
Mashup Score: 24GPER Stimulation Attenuates Cardiac Dysfunction in a Rat Model of Preeclampsia | Hypertension - 7 day(s) ago
BACKGROUND: Preeclampsia poses a substantial clinical challenge, characterized by maternal hypertension, cardiac dysfunction, and persistent cardiovascular risks for both the mother and offspring. Despite the known roles of the estrogen receptor (GPER [G protein-coupled estrogen receptor]) in placental development, its impact on cardiovascular aspects within a preeclampsia animal model remains unexplored. We propose that G-1, a GPER agonist, could have the potential to regulate not only hypertension but also cardiac dysfunction in rats with preeclampsia. METHODS: To explore the influence of G-1 on preeclampsia, we used the reduced uterine perfusion pressure (RUPP) model. RUPP rats were administered either G-1 (100 µg/kg per day) or hydralazine (25 mg/kg per day). We conducted echocardiography to probe the intricate cardiac effects of G-1. RESULTS: The RUPP rat model revealed signs of hypertension and cardiac dysfunction and alterations in gene and protein expression within placental an
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet-
GPER Stimulation Attenuates Cardiac Dysfunction in a Rat Model of Preeclampsia @allankdc @lab_lindsey https://t.co/G9ESNJtRk9 https://t.co/nOEEi9KkIe
-
Resistant hypertension was found associated with increased mortality only in those with increased 24-hour blood pressure. No differences were found between white-coat resistant hypertension and controlled hypertension @NatalieStaplin @ManuelGorostidi https://t.co/2kGNGHHOOW https://t.co/SOMVvyikSB